Skip to main content
Caplight Logo









Trogenix

Trogenix

Private
EdinburghHealthcare & Life Scienceshttps://trogenix.com/

Last Round

Series A

Oct 6, 2025

Total Funding Raised

$133.95M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Trogenix is a biotechnology company that develops precision cancer treatments using its proprietary Odysseus® genetic medicine platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

gene therapyprecision medicinesynthetic super-enhancersSSEoncologyAAV vectorsbioinformaticsdrug discoveryAI-driven designsolid tumorsglioblastomabiotechclinical-stage biotechgenetic medicineAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trogenix Comparables

Compare Trogenix with similar companies based on industry and business-model similarity.

Trogenix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Siren Biotechnology
79%
Chromatin Bioscience
79%
SynGenSys
77%

Trogenix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 6, 2025
SeedNov 18, 2024

Key People

Founding team and executive leadership

Ken Macnamara

Chief Executive Officer

Executive Team

Juan Manuel Iglesias

Chief Technology Officer

Executive Team

Tay Salimullah

Board Member Chief Strategy Officer

Executive Team

Trogenix Investors

Notable investors and investment history

Trogenix investors
InvestorRounds
4BIO CapitalSeries A, Seed
Meltwind AdvisorySeries A
IQ CapitalSeed, Series A
LongeVCSeries A
Old College CapitalSeed
Calculus CapitalSeries A
Cancer Research HorizonsSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 23, 2026

    Grew 17% QoQ, from 18 to 21 employees.

  • May 17, 2026

    Grew 18% QoQ, from 17 to 20 employees.

Trogenix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Trogenix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Trogenix's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdinburgh
Employee Range22
Year Founded2023
Last FundingOct 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?